CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 164 enrolled
Drug / intervention
Metformin (glucophage) +1 moredrug
Likely dose
Metformin (glucophage) 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01881828
NCT01881828Phase 3Completed

A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes

Jaeb Center for Health Research·interventional·Posted Jun 20, 2013·Updated Mar 3, 2020

In Brief

A Phase 3 clinical trial evaluating Metformin (glucophage) and oral placebo for Type 1 Diabetes. Completed, enrolled 164 participants across 1 site.

Detailed Summary

The objective of the proposed research is to evaluate the efficacy and safety of the use of metformin in addition to standard insulin therapy in overweight and obese children and adolescents, age 12-\<20 years, with type 1 diabetes for at least 1 year. Secondary objectives are to assess the effect of metformin on C-peptide levels, a measure of how much insulin is still being produced by the beta cells of the pancreas, and on vascular dysfunction. In addition, an ancillary study is planned to assess if metformin will improve tissue-specific insulin resistance in type 1 diabetes using a hyperinsulinemic euglycemic clamp.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 20, 2013
Enrollment StartSep 1, 2013
Primary CompletionSep 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 13.0 years ago

Interventions

Metformin (glucophage)drug

The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.

oral placeboother